Logo

Moderna Reports Results of COVID-19 Vaccine in P-II/III KidCOVE Study for the Treatment of COVID-19

Share this
Moderna Reports Results of COVID-19 Vaccine in P-II/III KidCOVE Study for the Treatment of COVID-19

Tuba Khan

Moderna Reports Results of COVID-19 Vaccine in P-II/III KidCOVE Study for the Treatment of COVID-19

Shots:

  • The P-II/III KidCOVE study evaluated the safety- tolerability- reactogenicity & effectivity of mRNA-1273 in 4753 children aged 6-12yrs. with COVID-19- administered as 28 days apart
  • The study met its primary immunogenicity EPs & interim analysis showed a robust neutralizing Ab response after two 50 μg doses of mRNA-1273. The therapy was well tolerated with a safety & tolerability profile that was consistent with the P-III COVE study in adolescents & adults
  • Additionally- all participants will be monitored for 12mos. after the 2nd dose to evaluate the long-term protection & safety. The company plans to submit the data to the US FDA- EMA- and other global regulatory imminently

Click here ­to­ read full press release/ article | Ref: Moderna | Image: The Indian Express

Click Here

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family